Clinical trial NCT01572519: A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma
Official title: An Open-label, Multicenter, Phase 1/2 Study of JNJ-40346527, an FMS Inhibitor, in Subjects With Relapsed or Refractory Hodgkin Lymphoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Relapsed or Refractory Hodgkin Lymphoma
Keywords: Relapsed Hodgkin lymphoma
Refractory Hodgkin lymphoma
JNJ-40346527
Dose-escalation
Pharmacokinetics
Lead sponsor: Janssen Research & Development, LLC
Sponsor class: INDUSTRY
First posted: 2012-04-06
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the safety, pharmacokinetics, and preliminary efficacy information of JNJ-40346527 in patients with relapsed or refractory Hodgkin lymphoma.

Detailed description: This is an open-label (individuals will know the identity of study treatments), dose-escalation study to evaluate the clinical efficacy, safety, and pharmacokinetics (PK; study of what the body does to a drug) of JNJ-40346527. Up to 38 subjects could be enrolled in the Phase 1 portion of the study and up to 30 subjects could be enrolled in the Phase 2 portion of the study (although planned, the study did not move forward to the Phase 2 portion). During the Phase 1 portion of the study, dose escalation of JNJ-40346527 will start at 150 mg (Cohort 1) once daily up to the maximum tolerated dose (MTD) or the highest planned dose (600 mg once daily); twice daily dosing may also be performed if deemed necessary. A Study Evaluation Team (SET) will review all available data after 1 cycle (21 days) of treatment for each cohort before any additional dose escalation occurs and will also determine the recommended Phase 2 dose for the expansion cohort. This study will consist of 3 periods: a screening period (from signing of informed consent until immediately before dosing), an open-label treatment period (from the first dose of study drug until the end-of-treatment visit), and a follow-up period (after the end-of-treatment visit). All patients will participate in the screening and treatment period. Patients will be administered JNJ-40346527 continuously until disease progression, or unacceptable toxicity (based on investigator assessment). The National Cancer Institute-Common Terminology Criteria for Adverse Events will be used to grade toxicity throughout the study. Disease response will be assessed according to the Revised Response Criteria for Malignant Lymphoma. Treatment will continue until disease progression or unacceptable toxicity (based on investigator assessment) occurs. Only patients who discontinue study drug before disease progression or discontinue due to treatment-related Grade 3 or higher toxicity will continue in the follow-up period. Serial PK samples will be collected in Cycle 1 as detailed in the protocol. Safety will be monitored throughout the study.

Eligibility criteria: Inclusion Criteria:

- Patients with histopathologically confirmed initial diagnosis of Hodgkin lymphoma and who have disease that has relapsed or is refractory that is progressing or active and requires treatment after at least 1 appropriate therapy

Exclusion Criteria:

* Known brain metastases or leptomeningeal disease
* Other malignancy within past 5 years
* Has any condition that, in the opinion of the investigator, would make study participation not be in the best interest (eg, compromise the well-being) of the patient or that could prevent, limit, or confound the protocol-specified assessments
* QTc prolongation at screening or other factors that increase the risk of QT prolongation such as diagnosis or family history of long-QT syndrome, diagnosed or suspected congenital long QT syndrome, or concomitant use of medication that can prolong the QT interval
* Taking CYP3A4 substrate drugs with a narrow therapeutic index (eg, alfentanil, astemizole, sirolimus, tacrolimus, terfenadine)

Primary outcomes:
measure: Phase 1 maximum tolerated dose (MTD) for JNJ-40346527
timeFrame: After completion of Cycle 1 (21 days of dosing) in the last subject in Phase 1
measure: Phase 2 overall response rate
timeFrame: Up to 6 months after the last subject is enrolled
Secondary outcomes:
measure: Duration of response (DOR)
timeFrame: Up to 6 months after the last subject is enrolled
measure: Progression-free survival (PFS)
timeFrame: Up to 6 months after the last subject is enrolled
measure: The number of participants affected by an adverse event
timeFrame: Up to 30 days after the last dose of study medication
measure: Maximum observed plasma concentration of JNJ-40346527
timeFrame: Up to treatment cycle Day 21
measure: Trough plasma concentration of JNJ-40346527
timeFrame: Up to treatment cycle Day 21
measure: Minimum observed plasma concentration of JNJ-40346527
timeFrame: Up to treatment cycle Day 21
measure: Time of maximum observed plasma concentration of JNJ-40346527
timeFrame: Up to treatment cycle Day 21
measure: Area under the plasma concentration-time curve of JNJ-40346527
timeFrame: Up to treatment cycle Day 21
measure: Total drug clearance of JNJ-40346527
timeFrame: Up to treatment cycle Day 21
measure: Accumulation index of JNJ-40346527
timeFrame: Up to treatment cycle Day 21
Other outcomes:
Locations:
city: Lille
country: France
city: Villejuif
country: France
city: Köln
country: Germany
city: Würzburg
country: Germany
Study officials:
affiliation: Janssen Research & Development, LLC
name: Janssen Research & Development, LLC Clinical Trial
role: STUDY_DIRECTOR
References: